Sign in

    Alexei Siniakov

    Research Analyst at Truist Securities

    Alexei Siniakov is the former Director of Corporate Finance and Equity Research Associate at Truist Securities, where he specialized in publicly traded real estate companies, particularly real estate investment trusts (REITs). Throughout his tenure, Siniakov delivered expert valuation analysis on firms such as Kite Realty Group and was recognized for strong financial planning, deal execution, and acquisitions following significant sector mergers. His career began in 2007 and includes strategic finance and capital markets roles at RBC Capital Markets, Dream, and most recently VP of Corporate Finance at Kite Realty Group before joining Lionheart Capital as Director of Finance in June 2023. Siniakov holds an M.B.A. from Ivey Business School, a Bachelor of Commerce from the University of Toronto, is a CFA charterholder, and has a robust FINRA registration history.

    Alexei Siniakov's questions to Kymera Therapeutics (KYMR) leadership

    Alexei Siniakov's questions to Kymera Therapeutics (KYMR) leadership • Q3 2024

    Question

    Speaking for Kripa Devarakonda, Alexei Siniakov of Truist Securities asked if a TYK2 degrader could address efficacy challenges seen with TYK2 inhibitors and whether future trials might enroll patients previously treated with a TYK2 inhibitor.

    Answer

    CEO Nello Mainolfi asserted that Kymera's degrader aims for a transformative, biologics-like profile by fully blocking TYK2 signaling, unlike inhibitors. CMO Jared Gollob added that initial studies would likely exclude patients who progressed on prior TYK2 inhibitors but might consider them in later-stage trials.

    Ask Fintool Equity Research AI